Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 11/20 | 1.00 |
| ▸ | CLK1 | P49759 | 8/20 | 1.00 |
| ▸ | CLK2 | P49760 | 7/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 2/20 | 0.54 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675234 | 1.00 | CLK4 (1.00) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675016 | 0.92 | CLK4 (0.84) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675150 | 0.86 | CLK4 (0.76) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675131 | 0.85 | CLK4 (1.00) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675095 | 0.83 | CLK4 (0.81) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675085 | 0.83 | CLK4 (0.70) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675287 | 0.82 | CLK4 (0.79) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675054 | 0.82 | CLK4 (1.00) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675235 | 0.82 | CLK4 (0.75) | CLK4CLK1CLK2DYRK1BDYRK1A | |
| SCHEMBL1675225 | 0.82 | CLK4 (0.69) | CLK4CLK1CLK2DYRK1BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4616854-A1 | TREATMENT OF MUSCLE SARCOPENIA | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025151669-A1 | CLK2 INHIBITION AS A RADIATION COUNTERMEASURE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | BROWN UNIVERSITY | 2023-06-15 | — | — | US | claimed |
| US-11452716-B2 | Pharmaceutical composition and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-27 | — | — | US | claimed |
| EP-4719447-A2 | METHOD TO GENERATE INDUCED RETINAL PROGENITOR CELLS AND TREATMENT USING SUCH CELLS | Academia Sinica (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12553028-B2 | Method to generate induced oligodendrocyte-lineage cells and treatment using such cells | ACADEMIA SINICA (TW) | 2026-02-17 | — | — | US | disclosed |
| US-20250304570-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2025190770-A1 | TREATMENT OF MUSCLE SARCOPENIA | MOLIUS SAGLIK TEKNOLOJILERI ANONIM SIRKETI (TR) | 2025-09-18 | — | — | WO | disclosed |
| EP-4616854-A1 | TREATMENT OF MUSCLE SARCOPENIA | Molius Saglik Teknolojileri Anonim Sirketi (TR) | 2025-09-17 | — | — | EP | disclosed |
| US-20230092294-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE | KUMQUAT BIOSCIENCES INC. | 2023-03-23 | — | — | US | disclosed |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | KUMQUAT BIOSCIENCES INC. | 2023-02-09 | — | — | US | disclosed |
| US-11452716-B2 | Pharmaceutical composition and use thereof | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-09-27 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| CN-109875999-B | Application of ponatinib in KIT mutant malignant melanoma | 上海交通大学医学院附属第九人民医院 | 2022-07-12 | — | — | CN | disclosed |
| US-11376257-B2 | Generation of muscle lineage cells and therapeutic uses thereof | SONIC MASTER LIMITED (VG) | 2022-07-05 | — | — | US | disclosed |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230092294-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE | MYD88, NFATC1, ICOS | CLK4 2224/4885CLK1 1159/4885CLK2 1262/4885 |
| US-12553028-B2 | Method to generate induced oligodendrocyte-lineage cells and treatment using such cells | HDAC4, HDAC9, MYT1 | CLK4 559/4885CLK1 1120/4885CLK2 1237/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | CLK4 2211/4885CLK1 1222/4885CLK2 1140/4885 |
| US-11452716-B2 | Pharmaceutical composition and use thereof | TP53, RB1, CDK20 | CLK4 793/4885CLK1 906/4885CLK2 358/4885 |
| US-11376257-B2 | Generation of muscle lineage cells and therapeutic uses thereof | MYLK2, MUSK, CKMT1A; CKMT1B | CLK4 463/4885CLK1 415/4885CLK2 265/4885 |
| US-20230044323-A1 | COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE ACTIVITY | NFATC1, MYD88, ICOS | CLK4 2429/4885CLK1 1318/4885CLK2 1355/4885 |
| US-20230183323-A1 | METHODS FOR PREVENTING, REVERSING OR TREATING A COVID-19 INFECTION | CHI3L1, CHI3L2, ACE2 | CLK4 4466/4885CLK1 4016/4885CLK2 4320/4885 |
| US-20250304570-A1 | BENZO-FUSED N-HETEROCYCLES AND USES THEREOF | NFATC1, BRCA1, MYD88 | CLK4 3165/4885CLK1 3393/4885CLK2 2194/4885 |
| US-11324827-B2 | Multifunctionalized polyethylene glycol derivative and preparation method therefor | HDGF, F11, F12 | CLK4 4026/4885CLK1 3586/4885CLK2 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.